Join the Odactra group to help and get support from people like you.
Odactra News
FDA Expands Indication of Dust Mite Allergy Drug to Include Young Children
WEDNESDAY, March 5, 2025 – The U.S. Food and Drug Administration has expanded its indication of Odactra, a house dust mite allergen tablet, for the treatment of house dust mite-induced allergic...
FDA Approves Odactra for the Treatment of House Dust Mite Allergy in Young Children
February 27, 2025 – ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s Odactra tablet for use in young children with house dust mite (HDM) a...
U.S. FDA Approves ALK's Odactra (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents
Odactra is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons 12 through 17 years of age, in addition to adults 18 through 65 years of...
FDA Approves Odactra for House Dust Mite Allergies
March 1, 2017 – The U.S. Food and Drug Administration today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced...